Regeneron Pharmaceuticals (REGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Regeneron Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$789.45+14.84(0.02%)Pre-market

Market Cap

$81.16B

P/E

18.7x

P/S

5.2x

P/B

2.6x

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

How this company scores

GoodMetricSide Score: 67/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Growth (15/25).

Profitability17/25

Growth15/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality16/25

Strengths

Strong marginsLow leverageConsistent free cash flowConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.7x5y range 8.4x – 27.1x

Currently near its 20-quarter median.

P/S · 5.2x5y range 3.9x – 8.4x

Currently near its 20-quarter median.

P/B · 2.6x5y range 1.8x – 4.0x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 8.2% — watch for continued compression, which may signal competitive or cost pressure.

Price & Volume

Market Cap $81.16B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $15.53B
Q. Revenue: $4.29B
TTM EBITDA: $4.64B
TTM Op. Income: $3.84B
Q. Op. Income: $1.29B
TTM Net Income: $4.33B
Q. Net Income: $1.30B
EPS: $12.62
Shares Out.: $102.80M

$15.53B in TTM revenue grew 9.3% YoY, reaching $4.29B last quarter. TTM EBITDA of $4.64B and TTM operating income of $3.84B show growth is flowing through to the bottom line. TTM net income of $4.33B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 33.0%
Op. Margin: 30.1%
Net Margin: 30.2%

Op. margin of 30.1% is up 0.8% YoY — cost efficiency is improving. Net margin at 30.2% Over the past year, operating margin is up 3% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 18.7x
P/S Ratio: 5.2x
P/B Ratio: 2.6x

At 18.7x P/E, the stock trades within typical market levels. P/S of 5.2x and P/B of 2.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 51% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $41.73B
Cash: $2.46B
Long-Term Debt: $1.99B
Book Value: $31.71B
D/E Ratio: 0.1
Debt/EBITDA: 1.4

With $41.73B in assets and $1.99B in long-term debt, D/E is 0.1and book value is $31.71B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $813.00M
TTM Free Cash Flow: $3.76B
FCF Margin: 24.2%
FCF / Net Income: 0.9

TTM FCF of $3.76B on $813.00M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 2% — a weakening trend.